Medical News

RSS

A drug that improves function of retinal blood vessels may be able to reduce the risk of stroke

The small study found that endothelial function is abnormal in eye blood vessels of patients who have early-stage hypertension, but that treatment with an angiotensin-receptor blocker (ARB) drug improves endothelial function. The endothelium is the lining of vessel walls and plays a key role in the vessels’ ability to relax and to constrict.

9 Apr 2004

Meningitis vaccination campaign in northeast Chad to fight epidemic

This weekend Médecins Sans Frontières (MSF) will be launching a meningitis vaccination campaign to fight an epidemic of meningitis A that has broken out in northeast Chad. The vaccination effort, covering 200,000 people, will take place in the Iriba and Guéréda districts, already hosting tens of thousands of refugees who have fled the war-torn region of Darfur in Sudan.

9 Apr 2004

Roche announces new dosing strategy

Roche has announced results from a study demonstrating that the new boosted dosing regimen for its protease inhibitor Invirase(R) (saquinavir 1000 mg with ritonavir 100 mg twice-daily) has no significant interactions when it is co-administered with tenofovir disoproxil fumarate (300 mg once-daily).

9 Apr 2004

DNA free radical damage research

Certain prostate cancer cell lines are unable to repair DNA damage caused by "free radicals," according to scientists at the National Institute of Standards and Technology (NIST) and National Institutes of Health (NIH). This type of damage has been implicated before in the development of prostate cancer, but the new research provides the first solid evidence that the normal repair process is altered in prostate cancer cells, possibly leading to a cascade of events that culminate in further DNA damage and cellular dysfunction.

9 Apr 2004

Magnetic tweezers that can manipulate strands of DNA

An array of magnetic traps designed for manipulating individual biomolecules and measuring the ultrasmall forces that affect their behavior has been demonstrated by scientists at the National Institute of Standards and Technology (NIST).

9 Apr 2004

New database for U.S. makers of in vitro diagnostic (IVD) medical devices

A new international database has been released that identifies measurement procedures and materials that will help U.S. makers of in vitro diagnostic (IVD) medical devices ensure that their products comply with European Union requirements.

9 Apr 2004

WHO update on Dengue fever in Indonesia

From 1 January to 4 April 2004 a total of 52,013, mainly hospitalized cases of dengue and 603 deaths have been registered with the Indonesian Ministry of Health. The overall case-fatality rate this year, particularly in Jakarta, has been lower than in previous years.

8 Apr 2004

WHO update on Meningococcal disease in Central African Republic

As of 31 March 2004, WHO has received reports of 43 cases and 7 deaths in the Central African Republic.

8 Apr 2004

Rare Burkina Faso strain of meningitis under control

A rare strain of meningitis, which re-emerged recently in Burkina Faso, would have left health authorities helpless just two years ago. Now, thanks to two years of work orchestrated by the World Health Organization (WHO), the strain (known as W135) has been rapidly identified and a mass action campaign is now controlling the outbreak.

8 Apr 2004

Hepatitis C wonder drug Ribasphere gets approval from FDA

The President and CEO of Three Rivers Pharmaceuticals, Donald J. Kerrish, RPh., stated, “The approval of Ribasphere™ marks a milestone in the treatment of HCV. Ribasphere™ is positioned to break down the economic barriers that have existed for the past decade in treating this chronic and potentially deadly disease.” Traditionally the cost of treatment for HCV can range from $20,000 – $25,000 annually. “Our aim is to bring affordable medicine to all individuals infected with this dreadful disease.” Mr. Kerrish continued.

8 Apr 2004

African summit on treatment of AIDS, tuberculosis and malaria

In Gaborone, Botswana, government officials and representatives of drug regulatory agencies from 23 nations, the research-based and generic pharmaceutical industries, public health leaders, health care providers, advocacy groups (including persons living with HIV/AIDS), academia and members of non-governmental organizations held discussions from March 29-31 on the scientific and technical principles for fixed-dose combination drug products (FDCs) for use in the treatment of AIDS, tuberculosis and malaria, the most serious infectious disease threats facing the world today.

8 Apr 2004

Cell research to eventually develop new treatments for cancer and disorders such as Parkinson’s and Huntington’s disease

Medical Research Council (MRC) scientists have made an important advance in understanding the biological processes involved when cells die. The work may help scientists to eventually develop new treatments for cancer and disorders such as Parkinson’s and Huntington’s disease.

8 Apr 2004

Unique heart arrhythmia drug represents one of the first molecular-based therapies for heart failure

Heart researchers at Columbia University Medical Center have developed and tested a unique heart arrhythmia drug that could prevent the sudden death of millions of people with heart failure as well as people with an inherited heart disorder. The drug represents one of the first molecular-based therapies for heart failure and avoids the toxicity of current treatments.

8 Apr 2004

New process to extract proteins from membranes by using chemicals

Proteins are complex compounds that are essential for the growth and repair of tissue. While scientists understand much about the structure and stability of water-soluble proteins that ‘float’ around in humans, they know very little about the shape and stability of proteins that are embedded, or folded, into the lipid membrane of cells. Such membrane proteins make up about 30 percent of all proteins in the body.

8 Apr 2004

New microgel could potentially recover any enzyme and save manufacturers considerable money

Carnegie Mellon University scientists have employed biological molecules to create a microgel that could recover costly enzymes for repeated use in catalyzing commercially important reactions. The microgel could potentially recover any enzyme and theoretically save manufacturers considerable money.

8 Apr 2004

Cervical cancer screening in Northern Ireland falls short

Only 72 per cent of women within the target age group in the Province had a cervical smear test in the five-year period up to 31 March 2003 – contrasting with higher figures for England, Scotland and Wales. NHS targets for cervical screening call for a minimum of 80 per cent of Northern Ireland women aged between 20 and 65 to be screened every five years.

8 Apr 2004

New AMA guide on treating foodborne illness

In partnership with a national nursing organization and several federal agencies, the AMA released an educational guide on April 7 about how health care professionals should identify and treat foodborne illnesses. "Diagnosis and Management of Foodborne Illnesses: A Primer for Physicians and Other Health Care Professionals" contains charts, scenarios and a continuing medical education section. It is free to health care professionals.

8 Apr 2004

Britain's NHS to buy large volume of mobile MRI scanners

British Health Secretary John Reid today invited bidders to supply the NHS with new, mobile, 'state of the art' MRI scanners and highly qualified staff to help cut waiting times across England. These new scanners will targeted at areas of greatest need. It's expected that they will be operational this summer.

8 Apr 2004

Breast-feeding may protect against SIDS

Breast-fed babies arouse more readily from deep sleep, Monash researchers have found, in a discovery that could help reduce deaths due to Sudden Infant Death Syndrome (SIDS).

7 Apr 2004

University of Florida researchers have used a common gel to successfully deliver gene therapy to the diaphragm

The technique, described in the current issue of Molecular Therapy, could eventually lead to a method to correct genetic conditions in humans that cause diaphragm weakness and respiratory failure -- a leading cause of death in tens of thousands of patients with forms of muscular dystrophy, including Pompe’s disease. Thousands of Americans with muscle-weakening diseases are placed on ventilators each year, according to the Muscular Dystrophy Association.

7 Apr 2004